Search News & Insights
Matheson Advises Zavante Therapeutics on its acquisition by Nabriva Therapeutics
Matheson recently advised San Diego based Zavante Therapeutics on its acquisition by Irish registered, NASDAQ listed, Nabriva Therapeutics plc. in a deal that involved the issuance of upfront consideration in the form of Nabriva shares.
Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.
Zavante is a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
Zavante was advised by a Matheson team which included Corporate M&A Partners, Fergus Bolster and Patrick Spicer, West Coast based Tax Partner, Mark O’Sullivan and Tax Senior Associate, Vahan Tchrakian.
Fergus Bolster said:
“We are very pleased to have acted, in conjunction with US advisers, for Zavante on this latest M&A transaction in the pharmaceuticals space. We, at Matheson, have particular expertise advising in relation to M&A and capital markets transactions involving equity issuances by Irish companies with US listings, and how to navigate the complexities where Irish and US securities and tax laws intersect.”
With a wealth of experience across our five partner led offices worldwide and a dedicated 100 person Corporate Department, Matheson has some of the most experienced corporate lawyers in Ireland and were named Ireland M&A Legal Adviser of the Year at the 2017 Mergermarket European M&A Awards. Excellence matters and Matheson’s Corporate Department, led by 20 partners, has unparalleled experience in complex and innovative domestic and international corporate transactions across all industry sectors.